English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/130254
COMPARTIR / IMPACTO:
Estadísticas
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Título

Treatment with a novel oleic-acid-dihydroxyamphetamine conjugation ameliorates non-alcoholic fatty liver disease in obese Zucker rats

AutorDecara, Juan Manuel; Pavón, Francisco Javier; Suárez, Juan Antonio; Romero-Cuevas, Miguel; Baixerás, Elena; Vázquez, Mariam; Rivera, Patricia M.; Gavito, Ana Luisa; Almeida, Bruno B De; Joglar, Jesús; De la Torre, R.; Rodríguez De Fonseca, Fernando; Serrano, Antonia M.
Palabras claveCannabinoid type 1 receptor
CB1
Non-alcoholic fatty liver disease
Obesity
Peroxisome proliferator activated-receptor α
PPAR-α
Zucker rats
Fecha de publicación1-oct-2015
CitaciónDMM Disease Models and Mechanisms
ResumenFatty liver disease is one of the main hepatic complications associated with obesity. To date, there are no effective treatments for this pathology apart from the use of classical fibrates. In this study, we have characterized the in vivo effects of a novel conjugation of oleic acid with an amphetamine derivative (OLHHA) in an animal model of genetic obesity. Lean and obese Zucker rats received a daily intraperitoneal administration of OLHHA (5 mg kg-1) for 15 days. Plasma and liver samples were collected for the biochemical and molecular biological analyses, including both immunohistochemical and histological studies. The expression of key enzymes and proteins that are involved in lipid metabolism and energy homeostasis was evaluated in the liver samples. The potential of OLHHA to produce adverse drug reactions or toxicity was also evaluated through the monitoring of interactions with hERG channel and liver cytochrome. We found that OLHHA is a drug with a safe pharmacological profile. Treatment for 15 days with OLHHA reduced the liver fat content and plasma triglyceride levels, and this was accompanied by a general improvement in the profile of plasma parameters related to liver damage in the obese rats. A decrease in fat accumulation in the liver was confirmed using histological staining. Additionally, OLHHA was observed to exert anti-apoptotic effects. This hepatoprotective activity in obese rats was associated with an increase in the mRNA and protein expression of the cannabinoid type 1 receptor and a decrease in the expression of the lipogenic enzymes FAS and HMGCR primarily. However, changes in the mRNA expression of certain proteins were not associated with changes in the protein expression (i.e. L-FABP and INSIG2). The present results demonstrate that OLHHA is a potential anti-steatotic drug that ameliorates the obesity-associated fatty liver and suggest the potential use of this new drug for the treatment of non-alcoholic fatty liver disease.
Versión del editorhttp://dx.doi.org/10.1242/dmm.019919
URIhttp://hdl.handle.net/10261/130254
DOI10.1242/dmm.019919
Aparece en las colecciones: (IQAC) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
DMMDisease2015.pdf3,74 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.